Assertio and Garda Push Back Tender Offer Launch to May 14, Keeping $21.80/share Deal Intact

Assertio Holdings (Nasdaq: ASRT) entered into a merger agreement with Garda Therapeutics on May 1, 2026. The agreement calls for Garda to acquire all outstanding Assertio shares for cash. A tender offer is the mechanism used to purchase those shares directly from investors.

- The tender offer launch is now set for May 14, 2026, up from the original date. - The offer price remains $21.80 per share, translating to $153.2 million in total cash consideration. - Assertio will file a Schedule 14D‑9 with the SEC on May 14, 2026, detailing the tender offer terms.

The delay gives both parties additional time to finalize regulatory preparations and shareholder communications. By keeping the price and structure unchanged, the deal’s economic terms stay stable, reducing uncertainty for investors. The upcoming Schedule 14D‑9 filing will provide the formal disclosure needed before the offer can proceed.